CHAMBER HILL STRATEGIES for SAGHMOS THERAPEUTICS, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare beneficiary access to a potential treatment to prevent contrast-induced acute kidney injury and major adverse renal and cardiac events after percutaneous coronary intervention, as well as potential savings to Medicare and beneficiaries to such prevention.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT | Counsel, U.S. House of Representatives, Committee on Energy and Commerce |
| JENNIFER BELL | Health Policy Advisor, Sen. Finance Committee |
| ANNA KATHERINE WEINSTEIN | — |
Health Issues HCR
Issues related to the policies proposed in the 21st Century Cures 2.0 Concept Paper. Education and awareness, generally, regarding treatment of contrast-induced acute kidney injury after percutaneous coronary intervention.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA BARTLETT | Counsel, U.S. House of Representatives, Committee on Energy and Commerce |
| JENNIFER BELL | Health Policy Advisor, Sen. Finance Committee |
| ANNA KATHERINE WEINSTEIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.